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Abstract
Background: Skin side effects during interferon-alpha and ribavirin treatment are common, but autoimmune
dermatosis triggered by interferon-alpha is rare. We describe a case of erythrodermia from exacerbated psoriasis
during the treatment of acute hepatitis C with pegylated-interferon-alpha and ribavirin. The incidence of psoriasis
in this circumstance is unknown and only 36 cases are described in the literature, of which only one describes an
erythrodermic psoriasis flare.
Case presentation: A 50-years old healthy white man presented with the complaints of headache, muscle pain,
appetite loss, yellow skin complexion and fatigue. The laboratory results showed elevated liver enzymes above 50 times
the upper limit of normal and a positive antibody test and RNA for hepatitis C. A screening test 6 months earlier was
negative and therefore the diagnosis of an acute hepatitis C infection was most likely. In the absence of spontaneous
clearance of the virus a therapy with pegylated- interferon-α and ribavirin was initiated. After 3 weeks the patient
developed red scaly papular skin lesions that evolved despite treatment with prednisone to a severe erythrodermia. A
skin biopsy showed typical signs for psoriasis vulgaris. Treatment with steroids was intensified and the hepatitis C therapy
stopped. The patient achieved sustained virological response for hepatitis C, but psoriatic lesions were still present
6 months after treatment.
Conclusion: Although autoimmune skin reactions under pegylated-interferon-α and ribavirin treatment are rare it
is important to recognise them early to start an adequate treatment to guarantee hepatitis C treatment continuation.
Keywords: Erythrodermia, Psoriasis, Acute hepatitis C, Pegylated-interferon-α
Introduction
Therapy of chronic hepatitis C (HCV) has changed from
treatment with pegylated interferon-α (peg-INF-α) and
ribavirin to combinations of direct acting agents (DAA’s)
that enable interferon- or even ribavirin-free regimens.
Interferon-free treatment regimens show cure rates >90 %,
shorter treatment durations and less side effects. But access
to DAA’s is limited to patients with chronic HCV infection
and because of financial constraints even to patients with
advanced liver damage (severe fibrosis or cirrhosis) in most
countries [1, 2]. The effect of DAA therapies in acute HCV
is not clear and data are lacking. Therefore treatment with
peg-INF-α +/- ribavirin for 12–24 weeks is still the standard
of care for acute HCV.
Treatment related skin reactions under interferon
therapy are common (13 %), but usually they are mild
and discontinuation of the drugs is not necessary [3, 4].
Injection site reactions are the most frequently encoun-
tered lesions. But also alopecia, eczematous drug reac-
tions, fixed drug or lichenoid eruptions, pigmentation
changes and sarcoidosis can be seen [3]. Seldom may an
autoimmune skin disease such as psoriasis or lupus
erythematodes be triggered by interferon treatment. We
describe a case of erythrodermia from exacerbated psor-
iasis during the treatment of acute HCV with peg-INF-α
and ribavirin.
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Case presentation
A 50 years old white man was sent to our outpatient clinic.
He started to feel sick a month before with headache,
muscle pain, appetite loss, yellow skin complexion and
fatigue. His medical history was unremarkable except for
two gout attacks years ago for which reason he was taking
allopurinol for more than 5 years. He ceased taking it as
soon as he felt sick. Alcohol consumption was three beers
per day. Sexual history revealed intercourse with two
women, homosexual contacts were negated. No intraven-
ous or nasal drug use and no tattoos were reported. The
clinical examination showed two red, erythrosquamous
plaques of 10x10mm and 5x5mm in diameter in the décol-
leté and scleral icterus. Sonography of the liver revealed
liver steatosis but no signs of fibrosis or cirrhosis. Liver
enzymes were elevated above 50 times the upper limit of
normal. HCV antibodies were positive. CMV, HIV and
hepatitis A and B serology were negative, EBV serology
consistent with past infection. The diagnosis of HCV geno-
type 1a was confirmed by HCV-RNA. Since a screening test
for HCV was negative six months ago we considered this
constellation despite a lacking transmission history as an
acute HCV infection. For the following 12 weeks transami-
nases and HCV-RNA were monitored to follow a potential
spontaneous HCV clearance (Fig. 1). Because the patient
remained viraemic we initiated a treatment for acute HCV
with 180 μg peg-INF-α weekly and 1000 mg ribavirin daily.
Two weeks after treatment initiation HCV-RNA was un-
detectable (Fig. 1).
At treatment week 3 the patient developed itching red
papules around 1 to 3 mm in diameter on the forearms
and feet. Some of them were confluent to plaques and
had a scaly aspect. Symptomatic treatment with cetiri-
zine and hydrating lotion was started. Over the next
weeks the exanthema was confluent and therapy with oral
prednisone (0.7 mg/kg body weight) was added at treat-
ment week 6 (Fig. 2). After an initial improvement the
exanthema worsened again. Serological tests for HIV and
syphilis were repeatedly negative and ribavirin was stopped
at week 9. At week 10 the whole therapy was ceased
because of increasing severe erythrodermia (Fig. 3). There
were no oral lesions. One week after treatment cessation
skin lesions aggravated further. A dermatologist was in-
volved and a skin biopsy performed. The biopsy showed
papillomatosis with vessel convolutes that reached the
stratum corneum as well as neutrophiles in the dermis and
parakeratosis consistent with psoriasis vulgaris (Fig. 4). Sys-
temic prednisone doses were further increased to 1 mg/kg
body weight (70 mg) and complemented with local whole
body clobetasol propionate applications. HCV-RNA was
not detectable at end of treatment and during follow up
consistent with a sustained virological response (Fig. 1).
Over the next weeks after HCV treatment cessation pred-
nisone could be tapered and replaced by 50 mg acitretin
per day. 6 months after treatment termination the pa-
tient still had some psoriatic lesions and acitretin was
maintained.
Discussion
Even though new interferon-free DAA therapies are avail-
able for the treatment of chronic HCV, standard therapy
for acute HCV remains peg-INF-α for 12–24 weeks (plus
ribavirin under certain conditions e.g. HIV/HCV-co-infec-
tion) [5]. Data of treatment for acute HCV with DAA’s is
lacking. Only one study in HIV/HCV co-infected men
who have sex with men showed an increased sustained
virological response at week 12 in patients treated with
Fig. 1 Liver enzymes, HCV-RNA over time
Fig. 2 Psoriatic skin lesions at treatment week 6
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combination therapy of telaprevir/peg-INF-α/ribavirin
compared to peg-INF-α/ribavirin alone [6]. Additionally
since access to interferon-free treatment is limited to
patients with advanced liver damage because of high
costs even treatment of chronic HCV with peg-INF-α
has still to be considered in rare cases.
Erythrodermic psoriasis is a rare but a severe and
disabling variant of psoriasis vulgaris [7]. The incidence
of psoriasis exacerbation by peg-INF-α therapy is un-
known, but several case reports were published [8–11].
One small uncontrolled explorative study with 28 patients
reported an occurrence of psoriasis in 2 % (3/28) [12]. A
case compilation by Afshar et al. found 36 cases of INF-α
associated psoriasis flares [8]; most cases were classic
plaque-type psoriasis vulgaris and only one patient showed
erythrodermic psoriasis. Most psoriasis flares happened
with an average delay of 1.6 months after interferon treat-
ment initiation but with a high inter-individual variation
(1 week -7 months) [8]. Our patient’s psoriatic flare was
early in the treatment course starting at week three and
showing the full picture of erythrodermic psoriasis at week
10. In our case treatment had to be stopped. This is usually
not necessary since mostly psoriatic skin side effects are
not severe and diminish after stopping therapy [8]. Retro-
spectively our patient had mild psoriatic lesions already at
the initial diagnosis of HCV infection. Since they seemed
well controlled without specific treatment at the time HCV
treatment with peg-INF-α was not contraindicated [13].
The report highlights the importance of a throughout
patient history and clinical examination at hepatitis C treat-
ment initiation and – most importantly – in regular inter-
vals thereafter. It is of utmost importance to recognise
autoimmune processes like psoriasis early to be able to
initiate an adequate therapy early and avoid hepatitis C
treatment interruptions. It should be noted that a well-
controlled psoriasis is not a contraindication to a treatment
with peg-INF-α and ribavirin since combination therapies
with immunosuppressive treatment seem safe [14].
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Fig. 4 Histopathology of the skin biopsy
Fig. 3 Erythrodermic psoriasis at treatment week 10
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